Candidates must hold a Ph.D. in neuroscience, protein biochemistry or cell biology and have a strong background in cell and animal models of AD or tauopathy. The ideal candidate will have strong assay development experience. The research will focus on supporting our small molecule tau oligomer inhibitor program. The work will include development and characterization of cell models of tau aggregation, and assessment of efficacy and compound mechanism of action in vivo. Experience in protein biochemistry or biophysics in a relevant field may also be considered.
Oligomerix, Inc. offers a stimulating research environment with established researchers interested in developing novel therapeutics for AD and related tauopathies, and supported by state-of-the-art research facilities.
Applications will be accepted on a rolling basis and candidates will be considered until the position is filled. To be considered, all applicants must submit in PDF format: a cover letter summarizing research experience and specifying the interests in this position; a curriculum vitae (including a full list of publications); a statement of research interests; and the names and contact details for three references. Please email this information to firstname.lastname@example.org. Oligomerix will select appropriate candidates to schedule interviews.
Candidates must hold a Ph.D. in neuroscience, protein biochemistry or cell biology and have a strong background in cell and animal models of AD or tauopathy.
Additional Salary Information: A salary history is required.
Internal Number: 10-30-18
About Oligomerix, Inc.
Oligomerix® is an early-stage biotechnology company focused on discovering and developing novel, small molecule tau aggregation inhibitors and companion biomarkers for Alzheimer’s disease and related neurodegenerative diseases with tau pathology. It has developed a highly novel and proprietary approach to targeting tau oligomer self-association at the beginning of the aggregation cascade. Its biomarker approach targets tau oligomer induced fragmentation. The Company, led by a highly qualified leadership team, has more than 12 years of tau research experience and over a decade of support from the NIA/NIH. Importantly, Oligomerix’s target and discovery approach has been validated via independent, blinded studies and key opinion leader reviews of its lead compound in vivo in a human tau mouse model.